{"entity":{"id":"medac","kind":"company","name":"medac","aka":["medac GmbH","medac Pharma"],"tldr":"medac is a German family-owned pharmaceutical company whose alkylating agent treosulfan, long used in Europe, was approved by the FDA in 2025 as conditioning treatment before stem cell transplantation in acute myeloid leukaemia and myelodysplastic syndromes.","summary":"medac GmbH, based in Wedel near Hamburg, is a privately held German company specialising in haematology, oncology, urology and autoimmune disease. Its alkylating agent treosulfan, approved in Europe for decades and marketed there as Trecondi for transplant conditioning, received FDA approval in January 2025 (Grafapex) with fludarabine as a preparative regimen before allogeneic haematopoietic stem cell transplantation in adults and children with acute myeloid leukaemia or myelodysplastic syndromes. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Medac","links":[{"label":"Official website","url":"https://www.medac.de/"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["aml","mds"],"sections":["chemotherapy","cell-therapy"],"technologies":[],"targets":[],"drugs":["treosulfan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Wedel","country":"DE","companyType":"pharma","website":"https://www.medac.de/","stage":"private-large","investors":[],"funding":[]},"route":"/companies/medac/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"}],"drug":[{"id":"treosulfan","kind":"drug","name":"Treosulfan","route":"/drugs/treosulfan/"}],"trial":[{"id":"nct00822393","kind":"trial","name":"Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)","route":"/trials/nct00822393/"}]}}